CN-10SHOULD CARBOXYPEPTIDASE BE USED MORE OFTEN SINCE ITS FDA APPROVAL? - A CASE OF SUCCESSFUL METHOTREXATE TOXICITY RESCUE IN A PATIENT WITH NEUROLYMPHOMATOSIS
Ly I, Romba M, Gobeske K, Mrugala M. CN-10SHOULD CARBOXYPEPTIDASE BE USED MORE OFTEN SINCE ITS FDA APPROVAL? - A CASE OF SUCCESSFUL METHOTREXATE TOXICITY RESCUE IN A PATIENT WITH NEUROLYMPHOMATOSIS. Neuro-Oncology 2014, 16: v48-v48. PMCID: PMC4218004, DOI: 10.1093/neuonc/nou243.10.Peer-Reviewed Original ResearchMTX toxicityCauda equinaMTX concentrationsT2/FLAIR hyperintensityDiffuse large B-cell lymphomaLarge B-cell lymphomaAcute communicating hydrocephalusCSF flow cytometryAcute kidney injuryHigh-dose methotrexateYear old womanRight abdominal wallB-cell lymphomaHemispheric sulciUrine alkalinizationHematologic toxicityKidney injurySpinal irradiationFDG avidityLeptomeningeal enhancementMTX levelsCommunicating hydrocephalusMature B cellsThoracic cordVentriculoperitoneal shunt